MICHAEL FRUMOVITZ to Prognosis
This is a "connection" page, showing publications MICHAEL FRUMOVITZ has written about Prognosis.
Connection Strength
0.469
-
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. Int J Gynecol Cancer. 2023 09 04; 33(9):1359-1369.
Score: 0.063
-
RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix: a NeCTuR study. J Gynecol Oncol. 2023 07; 34(4):e50.
Score: 0.060
-
Advanced stage (FIGO IVB) neuroendocrine cervical carcinoma. Int J Gynecol Cancer. 2022 11 07; 32(11):1469-1474.
Score: 0.059
-
Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol. 2016 Dec; 143(3):552-557.
Score: 0.039
-
Challenges in the diagnosis and management of cervical neuroendocrine carcinoma. Expert Rev Anticancer Ther. 2015; 15(7):805-10.
Score: 0.035
-
Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer. 2012 Sep; 22(7):1203-7.
Score: 0.029
-
Primary malignant melanoma of the vagina. Obstet Gynecol. 2010 Dec; 116(6):1358-1365.
Score: 0.026
-
Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther. 2006 Jan; 6(1):27-32.
Score: 0.018
-
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res. 2024 Oct 15; 30(20):4743-4754.
Score: 0.017
-
Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e431818.
Score: 0.017
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.012
-
Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer. Radiother Oncol. 2019 06; 135:58-64.
Score: 0.012
-
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
Score: 0.010
-
Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):546-553.
Score: 0.010
-
Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer. 2015 Oct; 25(8):1437-44.
Score: 0.009
-
Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Int J Gynecol Cancer. 2015 Sep; 25(7):1292-9.
Score: 0.009
-
Radical Trachelectomy for Early-Stage Cervical Cancer: A Survey of the Society of Gynecologic Oncology and Gynecologic Oncology Fellows-in-Training. Int J Gynecol Cancer. 2015 May; 25(4):681-7.
Score: 0.009
-
Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system? Gynecol Oncol. 2015 Feb; 136(2):269-73.
Score: 0.009
-
Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
Score: 0.008
-
Analgesic and antiemetic requirements after minimally invasive surgery for early cervical cancer: a comparison between laparoscopy and robotic surgery. Ann Surg Oncol. 2013 Apr; 20(4):1355-9.
Score: 0.007
-
Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol. 2007 Dec; 107(3):458-63.
Score: 0.005
-
Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006 Jun 01; 106(11):2452-8.
Score: 0.005